Increasing the Response of Mismatch Repair Proficient Rectal Cancer to Immunotherapy with Particle Radiation and DNA Damage Response Inhibitors—Preclinical Evidence
High-LET particle radiation and/or the use of concurrent DDRi with ICI have significant preclinical evidence of immunostimulatory effects in pMMR rectal adenocarcinoma and increased response rates to immunotherapy. The clinical evidence will be reviewed in the companion manuscript.
Authors
- Jake A. Kloeber (ORCID: https://orcid.org/0000-0002-6646-564X)
- Yasamin Sharifzadeh (ORCID: https://orcid.org/0000-0003-3269-3107)
- Alexander D. Sherry (ORCID: https://orcid.org/0000-0001-5115-1691)
- Cameron M. Callaghan (ORCID: https://orcid.org/0000-0001-9795-1424)
- Michael G. Haddock (ORCID: https://orcid.org/0000-0001-8966-744X)
- Sonja Dragojevic (ORCID: https://orcid.org/0000-0003-3971-8530)
- Kenneth W. Merrell (ORCID: https://orcid.org/0000-0002-3831-5644)
- Zhenkun Lou (ORCID: https://orcid.org/0000-0003-1938-3091)
- Jethwa Krishan
- Cristian Salazar-Vilches
- Daniel Ebner
- R. Mutter
- Jasvinder Singh
- Christopher L. Hallemeier
Institutions
- Mayo Clinic (US)
- WinnMed (US)
- Mayo Clinic in Arizona (US)
Publication Details
- Journal
- Cancers
- Published
- 2026-02-19
- DOI
- https://doi.org/10.3390/cancers18040682
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00